Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Multiple Myeloma Clinical Trial

— PrE1003  

Official title:

A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00790842
• Other study ID #: PrE1003
• Secondary ID: RV-MM-PrECOG-039
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: January 21, 2009
• Est. completion date: March 8, 2018

Study information

• Verified date: September 2018
• Source: PrECOG, LLC.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction.

Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.

Description:

Multiple Myeloma (MM) affects approximately 20,000 Americans annually and remains an incurable hematologic malignancy characterized by frequent early response followed by universal treatment relapse necessitating multiple sequential therapeutic regimens. Until recently, few effective therapies existed. Several novel agents for MM have now become available including the immunomodulatory drugs thalidomide, lenalidomide, as well as the proteasome inhibitor, bortezomib. Each of these agents is undergoing extensive clinical evaluation in combination with other therapies to produce unprecedented response rates in newly diagnosed and relapsed MM. Lenalidomide has proven to be a highly effective treatment agent, particularly when used in combination with dexamethasone but is renally excreted and little information is available about its use in myeloma patients with impaired kidney function (20% have renal failure at some time after diagnosis). Defining a safe and effective dose of lenalidomide to use is a critical step in MM treatment.

OUTLINE: This is a Phase I, dose-escalation study of lenalidomide followed by a Phase II study. Patients are stratified according to degree of renal dysfunction (moderate [creatinine clearance 30-60 mL/min] vs severe [creatinine clearance <30 mL/min and does not require dialysis] vs end-stage renal disease [creatinine clearance <30 mL/min and requires dialysis]).

Patients receive oral lenalidomide on days 1-21 and low-dose oral dexamethasone 40 mg on days 1, 8, 15, and 22. There is a 7 day rest (days 22-28) from lenalidomide. Each cycle is 28 days and repeated in the absence of disease progression or unacceptable toxicity.

Patients enrolled in the phase II portion of the study will undergo blood sample collection periodically for pharmacokinetic analysis of lenalidomide (Mayo Clinic sites only).

After completion of study treatment, patients are followed every 6 months for up to 3 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 63
• Est. completion date: March 8, 2018
• Est. primary completion date: September 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with previously treated multiple myeloma.

• Measurable disease assessed by one of the following =21 days prior to registration:

• Serum monoclonal protein =1 g by protein electrophoresis

• Urine monoclonal protein >200 mg on 24 hour electrophoresis

• Serum immunoglobulin free light chain =10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio

• Monoclonal bone marrow plasmacytosis =30% (evaluable disease)

• If both serum and urine m-components are present, both must be followed in order to evaluate response.

• All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued =2 weeks prior to registration.

• Age =18 years.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

• Acceptable organ and marrow function =21 days prior to registration:

• Absolute neutrophil count (ANC) =1000/mm³

• Platelet count =75,000/mm³

• Total bilirubin =2 mg/dL

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 x upper limit of normal

• Renal impairment at baseline as measured by serum creatinine clearance (CrCl) =60 mL/min =21 days prior to registration.

• Females of Childbearing Potential (FCBP) must have a negative pregnancy test within 10-14 days and again within 24 hours of starting Cycle 1 and must use an effective double-method contraception for =28 days prior to, during, and for =28 days after completion of study therapy.

• Able to take required prophylactic anticoagulation.

• Able to understand and willingness to sign a written informed consent.

• Willing to provide blood samples for research purposes (Mayo Clinic sites only).

• If previously received lenalidomide, demonstration of clinical response of any duration or stable disease with progression-free interval of =6 months from start of that therapy.

Exclusion Criteria:

• Concurrent use of other anti-cancer agents or treatments. Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to 20 mg of Prednisone per day as long as the dose has not been adjusted upwards in past 2 weeks prior to study registration.

• Uncontrolled intercurrent illness including, but not limited to, any of the following:

• Ongoing or active infection requiring IV antibiotics

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Uncontrolled cardiac arrhythmia

• Psychiatric illness/social situation that would limit compliance with study requirements.

• Any of the following as this regimen may be harmful to a developing fetus or nursing child:

• Pregnant women

• Breast-feeding women

• Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception.

• HIV-positive patients on combination antiretroviral therapy.

• Known hypersensitivity to thalidomide or other immunomodulatory drugs.

• History of Stevens-Johnson syndrome characterized by a desquamating rash while taking thalidomide or similar drugs.

• Other active malignancy except for non melanoma skin cancer or in situ cervical or breast cancer.

• Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Neoplasm
• Plasmacytoma

Intervention

Drug:
• Lenalidomide
Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
• Dexamethasone
40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
• Anticoagulants
Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.

Locations

Country	Name	City	State
United States	McFarland Clinic	Ames	Iowa
United States	Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor	Ann Arbor	Michigan
United States	Emory University Winship Cancer	Atlanta	Georgia
United States	University of IL at Chicago	Chicago	Illinois
United States	Kinston Medical Specialists	Kinston	North Carolina
United States	Gundersen Lutheran	La Crosse	Wisconsin
United States	WVU Mary Babb Randolph Cancer Center	Morgantown	West Virginia
United States	Missouri Valley Cancer Consortium	Omaha	Nebraska
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	Metro MN CCOP	Saint Louis Park	Minnesota
United States	Mayo Clinic in Arizona	Scottsdale	Arizona
United States	Siouxland Hematology Oncology Associates	Sioux City	Iowa
United States	Waukesha Memorial Hospital (ProHealth Care)	Waukesha	Wisconsin
United States	Aurora Cancer Center	Wauwatosa	Wisconsin
United States	Reading Hospital and Medical Center	West Reading	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
PrECOG, LLC.	Celgene

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 2018 Aug 29;8(9):86. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy	Dose Limiting Toxicity (DLT) was defined as any of the following events determined by the investigator to be possibly, probably, or definitely related to lenalidomide within the first cycle of therapy irrespective of whether the adverse events resolved: Grade 3 or higher neutropenia with fever =38.5 degrees C; Grade 4 neutropenia =7 days; Grade 4 or higher thrombocytopenia; Other non-hematologic Grade 4 or higher adverse event not present prior to starting therapy or not due to underlying cause	First cycle of therapy (28 days)
Primary	Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]	Per International Myeloma Working Group criteria, complete response (CR): negative immunofixation of serum and urine, normalization of free light chain (FLC) ratio if at study entry FLC was only measurable non-bone parameter, <5% plasma cells in bone marrow, disappearance of any soft tissue plasma cytomas; stringent complete response (sCR): all of above, + normal serum FLC ratio in all patients and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; partial response (PR): >=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to < 200 mg per 24 hours, >=50% decrease in difference between involved and uninvolved FLC levels or a 50% decrease in level of involved FLC with 50% decrease in ratio, >=50% reduction in bone marrow plasma cells, if baseline percentage was >=30%, >=50% reduction in size of soft tissue plasmacytoma; very good partial response (VGPR): PR + improvements in serum and urine M-components	56 months
Secondary	Overall Survival Time	Overall survival is the time from registration to death from any cause. Patients alive at the time of analysis were censored at the date last known alive.	56 months
Secondary	Duration of Response	Duration of response was defined as time between the onset of response and disease progression in months, among patients treated at the recommended phase II dose who experienced a response to treatment. Per criteria of the International Myeloma Working Group, progressive disease was defined as one of the following: increase of 25% from best confirmed response in serum M-component, urine M-component, free light chain (FLC), bone marrow plasma cell percentage, or development of new or increase in size of bone lesions or soft tissue plasma cytomas. Development of hypercalcemia that can be attributed solely to the myeloma also constituted progression.	56 months
Secondary	Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient	The highest degree of any adverse event experienced by each patient, as assessed by NCI CTCAE Version 4, with an attribution of possibly, probably, or definitely related to treatment. Reportable adverse events included those occurring while on treatment or within 30 days of the end of treatment.	56 months
Secondary	Renal Function Over Time	To describe renal function over time and to evaluate the safety profile of a onetime increase in lenalidomide dose at least 2 cycles after start of treatment due to improved renal function.	56 months
Secondary	Pharmacokinetics of Lenalidomide in Impaired Renal Function	To determine the pharmacokinetics of lenalidomide administration in myeloma patients with impaired renal function (pharmacokinetic analysis will be performed in up to 12 consented Mayo Clinic subjects treated during the Phase II component of the trial (only).	56 months
Secondary	Progression-free Survival	Progression-free survival is the time from registration to disease progression or death. Patients alive without disease progression were censored at the time of the last disease assessment.	56 months